Prevention of Arrhythmia Device Infection Trial (PADIT Pilot)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-12-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of the pilot study is to compare conventional antibiotic therapy to an aggressive antibiotic therapy plan for the prevention of arrhythmia device infection in high-risk patients undergoing arrhythmia device procedures. All antibiotics are approved for use and readily available.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Arrhythmia Device Infection Trial (PADIT)

NCT01613092

Arrhythmia

COMPLETED PHASE4

Prevention of Arrhythmia Device Infection Trial (PADIT)

NCT01628666

Arrhythmia

COMPLETED PHASE4

Randomized Assessment of Antibiotic Prophylaxis Prior to Port Placement

NCT05304871

Vascular Access Ports

WITHDRAWN NA

Prevention of Infections in Cardiac Surgery

NCT02285140

Thoracic Surgery Antibiotic Prophylaxis

TERMINATED NA

Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.

NCT02809131

Sick Sinus Syndrome Complete Heart Block Syncope +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infection can occur after surgery for either a pacemaker or an implantable defibrillation and can have very serious consequences. These infections are common and can be seen in as many as 2-3% of high-risk patients. Doctors use antibiotics to prevent these infections, but we do not know how much or how often to give the antibiotics to get the best effect. It is not known whether additional antibiotics during and after the operation would further reduce the risk of infection. This research study will compare two different ways of using common antibiotics to prevent infection during and following a device procedure. One way is the standard approach of a single dose before surgery and the other way uses more antibiotics. We do not know if either way is better. The purpose of this study therefore, is to compare two types of antibiotic therapy plans to better understand if one is most effective in preventing infection.

This study will provide the ability to evaluate the feasibility (i.e. site activation, enrollment, compliance, drop-out) and generate proof of concept for the larger clinical trial of 12,000 patients in all 25 Canadian Hospitals implanting ICDs, which will be submitted to the CIHR. Additionally, the study supports the continued initiatives of the network of physician investigators (Canadian Heart Rhythm Society Device Advisory Committee - CHRS DAC) collaborating to address arrhythmia procedures related clinical trials that will answer simple clinical questions that will focus initially on safety issues.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arrythmias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aggressive Antibiotic therapy

Patients receive preoperative intravenous antibiotics, intracavitary antibiotics during surgery and postoperative antibiotics.

Group Type EXPERIMENTAL

Cefazolin, Bacitracin, Cefalexin

Intervention Type DRUG

Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID

Conventional Antibiotic Therapy

Preoperative intravenous antibiotics

Group Type ACTIVE_COMPARATOR

Cefazolin

Intervention Type DRUG

Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cefazolin, Bacitracin, Cefalexin

Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID

Intervention Type DRUG

Cefazolin

Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 18 years
* One of the following planned device procedures:

* ICD, pacemaker, CRT-P, CRT-D generator and/or lead replacement or
* Pocket or lead revision or
* System upgrade (insertion or attempted insertion of leads) or
* New cardiac resynchronization therapy device implant (pacemaker or ICD)

Exclusion Criteria

* Unable or unwilling to provide written informed consent
* Unable or unwilling to complete the study follow-up schedule
* Life expectancy \< 12 months as per the opinion if the local investigator
* Allergy to or unable to tolerate cefazolin or clindamycin or vancomycin
* Allergy to or unable to tolerate intracavitary bacitracin or gentamicin or cefazolin
* Previously enrolled in this trial
* In another study that would confound the results of this trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No